Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus SOJOURN.
LARIN FE 1/20 vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
400 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive